As of June 21, 2025, Canntab Therapeutics Ltd (PILL.CN) reports a ROE (Return on Equity) of 1185.40%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Canntab Therapeutics Ltd's ROE (Return on Equity)
Over recent years, Canntab Therapeutics Ltd's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-05-31 | 1185.40% |
| 2021-05-31 | -194.81% |
| 2020-05-31 | -73.89% |
| 2019-05-31 | -108.41% |
| 2018-05-31 | -55.98% |
This slight downward trend highlights how Canntab Therapeutics Ltd manages its efficiency in generating profits from shareholders' equity over time.
Comparing Canntab Therapeutics Ltd's ROE (Return on Equity) to Peers
To better understand Canntab Therapeutics Ltd's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Canntab Therapeutics Ltd (PILL.CN) | 1185.40% |
| Trulite Inc (TRUL) | 2138.82% |
| Bevcanna Enterprises Inc (BEV.CN) | 335.42% |
| Indoor Harvest Corp (INQD) | 307.75% |
| BioMark Diagnostics Inc (BUX.CN) | 234.15% |
| Plymouth Rock Technologies Inc (PRT.CN) | 136.88% |
Compared to its competitors, Canntab Therapeutics Ltd's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.